We are live on ! Find out more
INBX icon

Inhibrx
INBX

88 hedge funds and large institutions have $149M invested in Inhibrx in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 34 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less capital invested

Capital invested by funds: $151M → $149M (-$2.03M)

2.43% less ownership

Funds ownership: 74.52% → 72.09% (-2.4%)

4% less funds holding

Funds holding: 92 → 88 (-4)

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

35% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 34

Holders
88
Holders Change
-4
Holders Change %
-4.35%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
10
Increased
22
Reduced
34
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$3.94M
2
State Street
State Street
Massachusetts
+$414K
3
RAM
Readystate Asset Management
Illinois
+$347K
4
Franklin Resources
Franklin Resources
California
+$287K
5
Millennium Management
Millennium Management
New York
+$264K

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$2.52M
2
BlackRock
BlackRock
New York
-$1.34M
3
ACH
ArrowMark Colorado Holdings
Colorado
-$1.34M
4
SC
Slotnik Capital
Texas
-$1.33M
5
PA
Perceptive Advisors
New York
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Viking Global Investors
1
Viking Global Investors
Connecticut
$25.5M – – –
S
2
Sanofi
France
$16.5M – – –
PA
3
Perceptive Advisors
New York
$14M -$1.11M -86,134 -8%
HighTower Advisors
4
HighTower Advisors
Illinois
$12.4M +$65 +5 +0%
BlackRock
5
BlackRock
New York
$10.4M -$1.34M -103,988 -12%
SI
6
Sofinnova Investments
California
$10.1M +$139K +10,762 +2%
WP
7
Woodline Partners
California
$9.46M +$3.94M +304,432 +85%
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.54M +$131K +10,125 +2%
Millennium Management
9
Millennium Management
New York
$3.94M +$264K +20,442 +8%
PHS
10
PFM Health Sciences
California
$3.49M -$2.52M -195,022 -44%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$3.23M -$440K -34,074 -13%
State Street
12
State Street
Massachusetts
$2.92M +$414K +32,055 +19%
CM
13
Caption Management
Oklahoma
$2.85M – – –
SC
14
Slotnik Capital
Texas
$2.63M -$1.33M -102,791 -36%
KCM
15
Kennedy Capital Management
Missouri
$2.53M +$160K +12,342 +7%
SSA
16
Schonfeld Strategic Advisors
New York
$2.21M +$137K +10,612 +7%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$1.71M -$936K -72,374 -38%
Northern Trust
18
Northern Trust
Illinois
$1.39M -$243K -18,828 -16%
GLF
19
Groupe la Francaise
France
$1.08M – – –
CIEC
20
Crédit Industriel et Commercial
France
$916K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$720K -$30K -2,322 -4%
UBS Group
22
UBS Group
Switzerland
$656K +$239K +18,516 +67%
IC
23
Ikarian Capital
Texas
$601K – – –
LNWWM
24
Laird Norton Wetherby Wealth Management
California
$580K +$526K +40,656 New
Fidelity Investments
25
Fidelity Investments
Massachusetts
$558K +$22.3K +1,724 +5%
1
2 3 4 5

INBX Hedge Fund Activity: Q2 2025 in Review

88 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q2 2025, worth a combined $149M — down 1.3% from $151M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of INBX and 10 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 22 added.

The largest buyer was Woodline Partners, adding an estimated $3.94M. The largest seller was PFM Health Sciences, cutting an estimated $2.52M.

  • 88 institutional investors held Inhibrx (INBX) as of Q2 2025, down from 92 in Q1 2025.
  • Funds reported $149M of Inhibrx stock for Q2 2025, down 1.3% quarter-over-quarter.
  • 10 funds opened new Inhibrx positions in Q2 2025 and 14 closed out, a net change of -4 holders.
  • The largest Inhibrx buyer in Q2 2025 was Woodline Partners, an estimated $3.94M added.
  • The largest Inhibrx seller in Q2 2025 was PFM Health Sciences, an estimated $2.52M sold.

Based on aggregated 13F filings for Q2 2025.